

European Partnership on Health Innovation






Important Disclaimer:

The purpose of this document is to present the status of discussions between 5 health industry associations. The content should not be considered as final or pre-emptive of final legislative decision about future public private partnerships under Horizon Europe.

EC website on Partnerships



The screenshot shows the European Commission website page for 'Candidates for European Partnerships in health'. The page features a blue header with the title and a sub-header: 'Details of candidates for European Partnerships under Horizon Europe. Partnership proposal, contact details, details of partners.' Below the header is a 'PAGE CONTENTS' section with links for 'Candidate details' and 'Candidates in other areas'. The main content area is titled 'Candidate details' and contains the following text:

The full list of candidate European Partnerships in Horizon Europe is found in Annex 7 of the [Orientations towards the first Strategic Plan for Horizon Europe](#).
The following are the candidate partnerships in the area of health.

European Partnership for Innovative Health (Initiative)

The initiative intends to

- create an EU-wide health research and innovation ecosystem that facilitates translation of scientific knowledge into innovations
- foster the development of safe, effective, people-centred and cost-effective innovations that respond to strategic unmet public health needs currently insufficiently served by industry
- drive cross-sectoral health innovation for a globally competitive European health industry

It will cover prevention, diagnostics, treatment and disease management.


[Draft partnership proposal](#) (July 2020)

Partners: European Coordination Committee of the Radiological, Electromedical and healthcare IT Industry (COCRI); European Federation of Pharmaceutical Industries and Associations (EFPIA); EuropaBio, MedTech Europe, VaccinesEurope

Contact
Commission services: RTD-HE@ec.europa.eu
Partners: contact@EUHealthIPP.org

At the bottom of the screenshot, there is a blue box with the word 'Link' in white text.

Timelines (tentative)



The COVID crisis calls for more and deeper partnering

- Proven relationship between sectors
 - pharma, diagnostic, vaccines, medical devices, digital health...
- Inter-relationship between national healthcare systems and EU initiatives
- Capacity to quickly mobilise all stakeholders at large scale

Biology promise and technology innovation has yet to gain more traction

New scientific & technological advancements have transformative potential

- Digital therapies appearing
- Precision therapies emerging
- Big data as a critical enabler to transforming healthcare

Multiple barriers for adoption

- Siloed approaches
- Different sets of standards
- Limited translation of science into products and services
- Reimbursement focusing on disease management
- Locked value of data analytics
- Interdisciplinary barriers in medical science

In response to this, we propose the cross-sector European Health Innovation PPP


A unique initiative

- **Push boundaries of the pre-competitive** space: mobilise and combine expertise across pharma, biologic, med tech and health IT
- **Pioneer paradigm changes** and cross-sector innovation
- **Strengthen translational research ecosystem** in Europe

Achieving goal through purposeful integration of

- **technologies and know-how**
 - **products and services**
 - clinical, community, social and informal **care workflows**
 - **business models and convergence of frameworks**
-

Health Innovation PPP - Towards people-centred health innovation



- **Improve patient journey and outcomes for healthcare systems**
- **Create resilient European translational R&D&I ecosystem**
- **Accelerate of translation of ideas into products and services**

Specific objectives

1. Better **understand determinants** of health and priority disease areas
2. **Integrate fragmented health R&I efforts** across sectors and technologies, academia and industry/public and private stakeholders, focussing on unmet public health needs
3. **Deliver tools**, data, platforms, technologies and processes **for improved prediction, prevention, interception, treatment and management of diseases**, meeting the needs of end users
4. Demonstrate **feasibility of people-centred, integrated health care** solutions along the health care pathway
5. **Exploit the full potential of digitalisation** and data exchange in health care
6. Deliver new and improved **methodologies and models for comprehensive assessment of the added value** of innovative and integrated health care solutions.

Draft Strategic Research Agenda (24 October 2019)

- **Improved patient journey and outcomes for healthcare systems**
- **Resilient translational R&D ecosystem**
- **Acceleration of translation of ideas into products and services**

- 1 Harness advances in and synergies in genetics, biology and technology innovations for less invasive, more precise and effective prevention, diagnosis, treatment and care
- 2 Develop patient-centric integrated care solutions along the healthcare continuum
- 3 Combine Big Data with advanced analytics/AI to enable R&D and products and services to support integrated healthcare approach
- 4 Engaging citizens and patients to manage and improve their health
- 5 Reinforce value initiatives to guide investment and rewarding of innovation in health and social care

How could it work?

Public private reflection on **challenges** that hold progress.

Multiple companies join forces,

combine (often) **proprietary knowledge, data and assets**

and open them up for challenge by and **collaboration with public partners**

Partners validate proposed solutions during project lifetime in R&D practice



**TOOLS
METHODOLOGIES**



**DATA
STANDARDS**




INFRASTRUCTURES



**DEMONSTRATORS
ACCELERATORS**

Stakeholders



What if we could help kids and adults with resistant asthma (50% of affected patients) to live normal lives?




The challenge

- 30 million people in Europe suffer from Asthma and are subject to a lifetime treatment.
- 60% do not or do poorly responds to standard steroid treatments.
- About 4% with severe asthma do not respond at all

Prospectively combining technologies, data, products and services to:

- Understand and address resistance
- Offer the most effective combinations of tools that helps effectively (self-) manage asthma by kids and adults

Big Data and advanced analytics/AI to enable effective AMR prevention, intervention and prediction



STANDARDISED AND INTEROPERABLE DATA ALLOWING FOR



A real-time dashboard consultation tool tracking pathogens' geographical prevalence, facilitating infection prevention and treatment tailoring



Information from “digital” biomarkers generated by patients/sick animals and the “healthy” population to accelerate development of new products



Reliable predictive models of resistance emergence to plan appropriate prevention and treatment interventions



AI and machine learning to generate dashboard and real-time decision tools for physicians in relationship with Health Electronic Records

Self-management of prostate cancer


To reduce overdiagnosis and overtreatment of indolent, in-time diagnostic of aggressive disease	An individualised decision support system tool	Web-based dashboard for personalised risk assessment
To equip patient with comprehensive information to make choice and do self management	Supports in therapy selection and monitoring of indolent disease	Combined with balanced information on the disease and lifestyle
Connected apps/devices to share data with physician		

Similar project can be applied to psychiatry: for unaffected individuals to avoid becoming patients and for patients who may accelerate their recovery or improve disease control

Patient-centric, integrated solutions along the care continuum for obesity

Health living/prevention

Solutions to manage health status and comorbidities of pre-obese, combining devices, health IT, etc



Ambulatory care/ In patient care

Solutions to optimise care pathway, combining pharma, surgery and service



Home long term care

Solutions to manage adherence and obesity comorbidities, combining health IT, service, device and pharma



European Partnership on Health Innovation

A multi-sector public-private partnership to sustain Europe at the forefront of medical innovation for the benefit of European citizens and healthcare systems

Understanding asthma and caring for patients with the disease

ASTHMA OVERVIEW

The World Health Organisation estimates that 235 million people suffer from asthma globally

- 1 Asthma is under-diagnosed and under-treated, creating a substantial burden to individuals, families and healthcare systems
- 2 Asthma is the most common chronic disease among children

IN EUROPE, 8.2% OF ADULTS AND 5.4% OF CHILDREN HAVE ASTHMA, WITH SUBSTANTIAL DIRECT AND INDIRECT COSTS TO PATIENTS, FAMILIES AND SOCIETY

To address the unmet medical needs of asthma patients, it is necessary to:

- Strengthen understanding of different asthma types
- Research genetic and environmental risk factors
- Develop knowledge about steroid resistant asthma
- Innovate using digital research solutions to combat air pollution

PUBLIC-PRIVATE PARTNERSHIP ON HEALTH INNOVATION

European healthcare is at a crossroads. It faces increasing challenges on a number of fronts; at the same time, technological and scientific advances offer new opportunities to solve these challenges. Only a cross-sectoral partnership bringing together stakeholders along the patient's journey can make significant progress towards unmet health needs like Asthma.

Five industry associations representing pharmaceutical, biotech and medical technologies industries operating in Europe (COOP, EFPIA, MedTech Europe, Europharma and Vaccines Europe) have come together to work on a Strategic Agenda for Innovation in Healthcare. This Agenda falls within the framework of the proposed European Health Innovation Public-Private Partnership (PHIP) under Horizon Europe. The examples here serve to illustrate areas of action as outlined in the Strategic Research Agenda but do not express a commitment to future projects, nor exclude other potential activities to address major challenges in this disease area.

European Partnership on Health Innovation

A multi-sector public-private partnership to sustain Europe at the forefront of medical innovation for the benefit of European citizens and healthcare systems

Going the extra mile: an integrative approach towards breast cancer prevention, diagnosis and care

BREAST CANCER OVERVIEW

Much has been achieved in breast cancer therapy in recent years:

- 1 Increased survival rates thanks to early detection and more targeted therapies
- 2 High awareness across Europe, with prevention forming an integral part of many national policies

In Europe, breast cancer remains a frequent cause of death, claiming the lives of more women on the continent than any other cancer.

98,735 WOMEN IN THE EU LOST THE BATTLE WITH BREAST CANCER IN 2018

Across the EU and in member states, better access to breast cancer care needs to be prioritised, including a focus on:

- Timely screening, diagnosis and care
- High-quality and innovative treatments
- Digital solutions for disease prevention and management
- Real-world research data

PUBLIC-PRIVATE PARTNERSHIP ON HEALTH INNOVATION

European healthcare is at a crossroads, with breast cancer diagnosis and care as one of its top challenges. At the same time, technological and scientific advances present significant new opportunities for innovations. Only a cross-sectoral partnership bringing together stakeholders along the patient's journey can make significant progress towards unmet health needs like breast cancer.

Five industry associations representing pharmaceutical, biotech and medical technologies industries operating in Europe (COOP, EFPIA, MedTech Europe, Europharma and Vaccines Europe) have come together to work on a Strategic Agenda for Innovation in Healthcare. This Agenda falls within the framework of the proposed European Health Innovation Public-Private Partnership (PHIP) under Horizon Europe. The examples here serve to illustrate areas of action as outlined in the Strategic Research Agenda but do not express a commitment to future projects, nor exclude other potential activities to address major challenges in this disease area.

European Partnership on Health Innovation

A multi-sector public-private partnership to sustain Europe at the forefront of medical innovation for the benefit of European citizens and healthcare systems

An integrated initiative to optimize future obesity treatment

OBESITY OVERVIEW

Weight problems and obesity are increasing at a rapid rate in most EU Member States

- 1 Obesity significantly increases the risk of chronic diseases such as type 2 diabetes, hypertension, coronary heart diseases and certain cancers
- 2 Obesity and its complications have substantial direct and indirect costs that put a considerable strain on healthcare and social resources

ESTIMATES SHOW THAT 51.6% OF THE EU'S POPULATION (18 & OVER) IS OVERWEIGHT

Prevention and treatment of obesity and its complications can be optimized with:

- Integrated approaches for diagnosis, treatment and care
- Embracing patient-centric care solutions
- 'Big data' and digital solutions to research obesity development
- Empowering citizens and patients to improve their health

PUBLIC-PRIVATE PARTNERSHIP ON HEALTH INNOVATION

Healthcare in Europe is at a crossroads. It faces increasing challenges on a number of fronts; at the same time, technological and scientific advances offer new opportunities to solve these challenges. Only a cross-sectoral partnership bringing together stakeholders along the patient's journey can make significant progress towards addressing unmet health needs like obesity.

Five industry associations representing pharmaceutical, biotech and medical technologies industries operating in Europe (COOP, EFPIA, MedTech Europe, Europharma and Vaccines Europe) have come together to work on a Strategic Agenda for Innovation in Healthcare. This Agenda falls within the framework of the proposed European Health Innovation Public-Private Partnership (PHIP) under Horizon Europe. The examples here serve to illustrate areas of action as outlined in the Strategic Research Agenda but do not express a commitment to future projects, nor exclude other potential activities to address major challenges in this disease area.

Industry web site on Health Partnership

- www.euhealthppp.org
- Strategic Research & Innovation Agenda
- Case studies as examples
 - Asthma
 - Breast Cancer
 - Obesity
 - More to come in coming weeks



The screenshot shows the homepage of the European Partnership for Health Innovation website. The header features the title "European Partnership for Health Innovation" and a navigation menu with links for "Home", "Blog", "Case studies", "Consultation", and "Privacy policy". The main content area has a dark blue background with the title "Why a European Partnership for Health Innovation?" and a paragraph of text: "Healthcare in Europe is at a crossroads. It faces increasing challenges on a number of fronts; at the same time, technological and scientific advances offer new opportunities to solve these challenges. Bridging the gap to address today's health and translational challenges will require a multi-sector Public-Private Partnership."

Is the Health PPP the right tool to foster health innovation in EU?

- Attractive innovation ecosystem (scientific excellence, easy access to stakeholders along the value chain, recognised clinical excellence, de-risking industrial investments at early stage of R&D)
- Proximity and access to end-users (patients, healthcare systems)
- Financial investment capacity at scale to address unmet medical needs
- Continuity and sustainability of support to R&D&I over mid-term (>5 years)